Cytokinetics, Incorporated (CYTK) is a Healthcare stock trading at $78.68 (as of 2026-06-18), with a market capitalization of $9.55B and a trailing P/E of -10.2. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Cytokinetics develops and commercializes small-molecule therapies intended to affect muscle function, including muscle activators and inhibitors. Its pipeline includes cardiac and skeletal muscle candidates such as omecamtiv mecarbil and reldesemtiv, with additional programs in clinical stages for conditions including heart failure, amyotrophic lateral sclerosis, spinal muscular atrophy, and hypertrophic cardiomyopathy.